Western Union Expands in the Philippines with Cebuana Lhuillier
28.7.2020 16:00:00 EEST | Business Wire | Press release
Western Union (NYSE:WU), a global leader in cross-border, cross-currency money movement and payments, and Cebuana Lhuillier, the largest and long-tenured microfinancial service provider in the Philippines, have come together to enable customers in the Philippines to send and receive Western Union money transfers.
The significant collaboration with Cebuana Lhuillier adds 2,500 more locations to Western Union’s global network and will provide greater access to customers in the world’s fourth largest remittance receiving country. Money transfer customers accessing Cebuana Lhuillier’s nationwide branch network will be able to send or receive money via Western Union’s global network in more than 200 countries and territories. The services are expected to be rolled out in the coming weeks.
“Western Union and Cebuana Lhuillier understand the importance of connectivity and building relationships, while keeping customers at their core. This strategic collaboration and integration of capabilities of two leaders highlights the power of combined assets to meet customer’s needs,” said Jean Claude Farah, President, Global Network, Western Union.
Farah added, “In an age when speed, reliability and convenience mean everything, we are increasing the number of touchpoints where our customers can access our services and connect with their loved ones around the world. We welcome Cebuana Lhuillier to the Western Union family and are proud and excited to work collaboratively to reach more customers together.”
After successfully serving Filipinos for decades offering vital financial services, the two companies have joined forces to advance cross-border money movement for customers in the Philippines. This alliance supports Western Union’s strategy to leverage its platform and portfolio of capabilities, enabling other businesses looking to expand their global reach and build upon a robust partnership. The cooperation between the two companies also puts forward Cebuana Lhuillier’s vision of empowering Filipinos through financial services.
“This partnership with Western Union is a prudent step in ensuring accessibility for the millions of Filipinos around the world and in paving the way for a future-proof network with presence in almost all parts of the globe,” said Jean Henri Lhuillier, President and CEO of Cebuana Lhuillier.
“We are more than thrilled to collaborate with Western Union as their company values line up perfectly with our core of facilitating financial inclusion for the underserved Filipinos and expanding our reach makes that all the more possible,” added Lhuillier.
Cebuana Lhuillier is a one-stop shop that offers microfinancial services to over 30 million clients through its more than 2,500 branches with 20,000 domestic partners and 1.7 million physical and virtual touchpoints. The company is also acting as a cash agent for Cebuana Lhuillier Rural Bank and has since provided a bank account to 4 million previously unbanked Filipinos since the launch of the rural bank’s revolutionary product Cebuana Lhuillier Micro Savings.
Western Union serves customers globally from a fast-growing digital network of web, app, and the largest Agent retail locations across the world. In addition, Western Union’s global payout network includes billions of bank accounts and wallets offering unparalleled convenience to families and loved ones sending money to the Philippines. In the Philippines, customers will soon be able to send and receive through Cebuana Lhuillier and may check the Agent Locator link for the status of their nearest locations.
About Western Union
The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of March 31, 2020, our network included over 550,000 retail agent locations offering our branded services in more than 200 countries and territories, with the capability to send money to billions of accounts. Additionally, westernunion.com, our fastest growing channel in 2019, is available in over 75 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends, and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com.
About Cebuana Lhuillier
P.J. Lhuillier, Inc. (PJLI) is the proud parent company of Cebuana Lhuillier, the Philippines’ largest microfinancial services provider that offers pawning, remittance, micro insurance, bills payment, e-load, business-to-business solutions services, and micro savings and other banking services through their banking arm, the Cebuana Lhuillier Rural Bank. For more than 30 years, Cebuana Lhuillier continuously provides fast, easy, secure, and convenient microfinancial products and services to more than 30 million customers through over 2,500 branches nationwide. The company has also expanded its services into the digital space through the eCebuana App, a product of the Cebuana Lhuillier Rural Bank, and a host of other financial platforms such as Cebuana From Home, ProtectNow.com and the Cebuana Lhuillier Jewelry website.
Cebuana Lhuillier is committed to its purpose of bringing financial inclusion to the majority of Filipinos and has remained at the forefront of its industry through its many product innovations and leadership in customer service. Its commitment to excellence has given rise to many countless accolades and recognitions here and abroad.
WU-G
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005065/en/
Contact information
Media Contacts:
Western Union Global Communications
Pia De Lima: pia.delima@wu.com
Western Union Asia-Pacific
Karen Santos: Karen.Santos2@westernunion.com
Cebuana Lhuillier
Melanie Suzon: mmsuzon@pjlhuillier.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
